The race to produce the first CAR-T, a technology capable of reprograming a cancer patient's white blood cells to kill tumor cells, has reached its next phase, thanks to Novartis. In Forbes, Samuele Butera, the Global Business Leader for Cell & Gene Therapies at Novartis, explains the company’s work in fighting cancer within the body.